Principal Financial Group Inc Crinetics Pharmaceuticals, Inc. Transaction History

Principal Financial Group Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 31, 2024	BUY	$43.83 - $54.98 $2.83 Million - $3.55 Million	64,504 Added 488.48%	77,709 $3.97 Million
Q2 2024 Jul 29, 2024	SELL	$42.12 - $51.91 $74,594 - $91,932	-1,771 Reduced 11.83%	13,205 $591,000
Q1 2024 Apr 29, 2024	SELL	$34.76 - $46.81 $31,596 - $42,550	-909 Reduced 5.72%	14,976 $701,000
Q4 2023 Feb 07, 2024	SELL	$25.62 - $37.07 $36,277 - $52,491	-1,416 Reduced 8.18%	15,885 $565,000
Q3 2023 Nov 02, 2023	BUY	$15.97 - $30.59 $58,274 - $111,622	3,649 Added 26.73%	17,301 $514,000
Q2 2023 Aug 07, 2023	SELL	$15.73 - $23.6 $5,285 - $7,929	-336 Reduced 2.4%	13,652 $246,000
Q1 2023 May 09, 2023	BUY	$15.31 - $21.1 $25,322 - $34,899	1,654 Added 13.41%	13,988 $224,000
Q4 2022 Feb 09, 2023	BUY	$15.49 - $19.05 $191,053 - $234,962	12,334 New	12,334 $225,000
Q1 2022 May 09, 2022	SELL	$17.15 - $28.31 $125,109 - $206,521	-7,295 Closed	0 $0
Q4 2021 Feb 09, 2022	BUY	$19.35 - $28.41 $141,158 - $207,250	7,295 New	7,295 $207,000

241

79.5M

23.3K

44.3K

Ticker CRNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,752,800
Market Cap $2.88B
Description
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

Stay updated on Principal Financial Group Inc with notifications on news.